Why are there no clinically-approved drugs targeting disordered proteins?

Area of Science:

• Biochemistry
• Drug Discovery
• Structural Biology

Background:

• Intrinsically disordered proteins (IDPs) and regions (IDRs) play crucial roles in biological regulation and disease.
• Their dynamic, ensemble nature presents unique challenges for drug development compared to folded proteins.
• Current drug discovery efforts have largely underexploited IDPs due to these complexities.

Purpose of the Study:

• To identify and analyze key barriers hindering the therapeutic exploitation of IDPs.
• To highlight the need for new approaches in drug design targeting IDPs.
• To emphasize the necessity for improved data resources and methodologies for IDP research.

Main Methods:

• Analysis of existing biological databases, including the Biological Magnetic Resonance Data Bank (BMRB) and BindingDB.
• Review of nontraditional binding mechanisms characteristic of IDPs.
• Assessment of experimental and computational limitations in studying disordered systems.

Main Results:

• IDPs and IDRs are significantly underrepresented in current binding and structural databases.
• Classical drug design principles are often inadequate for targeting the transient and multivalent interactions of IDPs.
• Significant gaps exist in experimental and computational tools for characterizing IDP behavior.

Conclusions:

• Addressing the identified barriers is crucial for advancing IDP-targeted drug discovery.
• Developing novel binding paradigms and tailored methodologies is essential.
• Establishing community-driven, standardized datasets will accelerate the harnessing of IDPs as a therapeutic frontier.